Seminars in Radiation Oncology
Volume 19, Issue 3 , Pages 150-154 , July 2009

Chemotherapy for Malignant Gliomas

  • Teri N. Kreisl, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Teri N. Kreisl, MD, Neuro-Oncology Branch, National Cancer Institute, NIH, 9030 Old Georgetown Road, Bldg 82, Bethesda, MD 20892

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96
  2. Keles GE, Anderson B, Berger MS. The effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere. Surg Neurol. 1999;52:371–379
  3. Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: Prognosis, extent of resection, and survival. J Neurosurg. 2001;95:190–198
  4. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst. 1998;90:1473–1479
  5. Calatozzolo C, Gelati M, Ciusani E, et al. Expression of drug resistance proteins Pgp, MRP1, MRP3, MRP5 and GST-pi in human glioma. J Neuro-oncol. 2005;74:113–121
  6. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–996
  7. Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse (Temodal Brain Tumor Group). J Clin Oncol. 1999;17:2762–2771
  8. Tolcher AW, Gerson SL, Denis L, et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer. 2003;88:1004–1011
  9. Chakravarti A, Erkkinen MG, Nestler U, et al. Temozolomide-mediated radiation enhancement in glioblastoma: A report on underlying mechanisms. Clin Cancer Res. 2006;12:4738–4746
  10. van Nifterik KA, van den Berg J, Stalpers LJ, et al. Differential radiosensitizing potential of temozolomide in MGMT promoter methylated glioblastoma multiforme cell lines. Int J Radiat Oncol Biol Phys. 2007;69:1246–1253
  11. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997–1003
  12. Kong DS, Lee JI, Kim WS, et al. A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma. Oncol Rep. 2006;16:1117–1121
  13. Perry JR, Rizek P, Cashman R, et al. Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: The “rescue” approach. Cancer. 2008;113:2153–2157
  14. Wick A, Felsberg J, Steinbach JP, et al. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol. 2007;25:3357–3361
  15. Fornier M, Norton L. Dose-dense adjuvant chemotherapy for primary breast cancer. Breast Cancer Res. 2005;7:64–69
  16. Orlando L, Cardillo A, Rocca A, et al. Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer. Anticancer Drugs. 2006;17:961–967
  17. Quinn JA, Desjardins A, Weingart J, et al. phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol. 2005;23:7178–7187
  18. Solero CL, Monfardini S, Brambilla C, et al. Controlled study with Bcnu v Ccnu as adjuvant chemotherapy following surgery plus radiotherapy for glioblastoma multiforme. Cancer Clin Trials. 1979;2:43–48
  19. Walker MD. Chemotherapy: Adjuvant to surgery and radiation therapy. Semin Oncol. 1975;2:69–72
  20. Walker MD, Green SB, Byar DP, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med. 1980;303:1323–1329
  21. Fine HA. The basis for current treatment recommendations for malignant gliomas. J Neurooncol. 1994;20:111–120
  22. Yung WK, Mechtler L, Gleason MJ. Intravenous carboplatin for recurrent malignant glioma: A phase II study. J Clin Oncol. 1991;9:860–864
  23. Warnick RE, Prados MD, Mack EE, et al. A phase II study of intravenous carboplatin for the treatment of recurrent gliomas. J Neurooncol. 1994;19:69–74
  24. Franceschi E, Cavallo G, Scopece L, et al. Phase II trial of carboplatin and etoposide for patients with recurrent high-grade glioma. Br J Cancer. 2004;91:1038–1044
  25. Fulton D, Urtasun R, Forsyth P. Phase II study of prolonged oral therapy with etoposide (vp16) for patients with recurrent malignant glioma. J Neurooncol. 1996;27:149–155
  26. Jeremic B, Grujicic D, Jevremovic S, et al. Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma: A phase II study. J Clin Oncol. 1992;10:1074–1077
  27. Ashby LS, Shapiro WR. Intra-arterial cisplatin plus oral etoposide for the treatment of recurrent malignant glioma: A phase II study. J Neurooncol. 2001;51:67–86
  28. Dropcho EJ, Rosenfeld SS, Vitek J, et al. Phase II study of intracarotid or selective intracerebral infusion of cisplatin for treatment of recurrent anaplastic gliomas. J Neurooncol. 1998;36:191–198
  29. Fortin D, Desjardins A, Benko A, et al. Enhanced chemotherapy delivery by intraarterial infusion and blood–brain barrier disruption in malignant brain tumors: The Sherbrooke experience. Cancer. 2005;103:2606–2615
  30. Gumerlock MK, Belshe BD, Madsen R, et al. Osmotic blood–brain barrier disruption and chemotherapy in the treatment of high grade malignant glioma: Patient series and literature review. J Neurooncol. 1992;12:33–46
  31. Williams PC, Henner WD, Roman-Goldstein S, et al. Toxicity and efficacy of carboplatin and etoposide in conjunction with disruption of the blood–brain tumor barrier in the treatment of intracranial neoplasms. Neurosurgery. 1995;37:17–27
  32. Stefanik DF, Fellows WK, Rizkalla LR, et al. Monoclonal antibodies to vascular endothelial growth factor (VEGF) and the VEGF receptor, FLT-1, inhibit the growth of C6 glioma in a mouse xenograft. J Neurooncol. 2001;55:91–100
  33. Vredenburgh JJ, Desjardins A, Herndon JE, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007;13:1253–1259
  34. Vredenburgh JJ, Desjardins A, Herndon JE, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25:4722–4729
  35. Batchelor TT, Gilbert MR, Supko JG, et al. Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: Final report of NABTT 97-11. J Neurooncol. 2004;6:21–27
  36. Prados MD, Lamborn K, Yung WK, et al. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study. J Neurooncol. 2006;8:189–193
  37. Cloughesy TF, Prados MD, Wen PY, et al: A phase II, randomized, noncomparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (cpt) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM). ASCO Meeting Abstracts. Chicago, IL. May 20, 2008
  38. Chaskis C, Sadones J, Michotte A, et al: A phase II trial of sunitinib in patients with recurrent high-grade glioma: ASCO Meeting Abstracts. Chicago, IL. May 20, 2008
  39. Nabors LB, Rosenfeld M, Chamberlain M, et al: A phase I trial of sorafenib (BAY 43-9006) for patients with recurrent or progressive malignant glioma (NABTT 0401): ASCO Meeting Abstracts. Chicago, IL. June 20, 2007
  40. Smith JS, Tachibana I, Passe SM, et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst. 2001;93:1246–1256
  41. Nathoo N, Goldlust S, Vogelbaum MA. Epidermal growth factor receptor antagonists: Novel therapy for the treatment of high-grade gliomas. Neurosurgery. 2004;54:1480–1488
  42. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med. 2005;353:2012–2024
  43. Rich JN, Reardon DA, Peery T, et al. phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol. 2004;22:133–142
  44. Bent MVD, Brandes A, Rampling R, et al: Randomized phase II trial of erlotinib (E) versus temozolomide (TMZ) or BCNU in recurrent glioblastoma multiforme (GBM): EORTC 26,034: paper presented at Abstracts for The Twelfth Annual Meeting of the Society for Neuro-Oncology. Dallas, TX. October 1 2007
  45. Wen PY, Yung WK, Lamborn KR, et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium study 99-08. Clin Cancer Res. 2006;12:4899–4907
  46. Reardon DA, Egorin MJ, Quinn JA, et al. phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol. 2005;23:9359–9368
  47. Cloughesy TF, Wen PY, Robins HI, et al. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: A North American Brain Tumor Consortium study. J Clin Oncol. 2006;24:3651–3656
  48. Fine HA, Puduvalli VK, Chamberlain MC, et al: Enzastaurin (ENZ) versus lomustine (CCNU) in the treatment of recurrent, intracranial glioblastoma multiforme (GBM): A phase III study: ASCO Meeting Abstracts. Chicago, IL. May 20, 2008
  49. Doherty L, Gigas DC, Kesari S, et al. Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology. 2006;67:156–158
  50. Galanis E, Buckner JC, Maurer MJ, et al. phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A North Central Cancer Treatment Group study. J Clin Oncol. 2005;23:5294–5304
  51. Nguyen TD, Lassman AB, Lis E, et al: A pilot study to assess the tolerability and efficacy of RAD-001 (everolimus) with gefitinib in patients with recurrent glioblastoma multiforme (GBM). ASCO Meeting Abstracts. Atlanta, GA. June 20, 2006
  52. Camphausen K, Tofilon PJ. Inhibition of histone deacetylation: A strategy for tumor radiosensitization. J Clin Oncol. 2007;25:4051–4056
  53. Galanis E, Jaeckle KA, Maurer MJ, et al: N04 7B: NCCTG phase II trial of vorinostat (suberoylanilide hydroxamic acid) in recurrent glioblastoma multiforme (GBM). ASCO Meeting Abstracts. Chicago, IL. June 20, 2007
  54. Dicker A, Werner-Wasik M, Machtay M, et al: A phase I trial using the proteasome inhibitor bortezomib and concurrent temazolomide and radiotherapy for high grade gliomas. ASCO Meeting Abstracts. Chicago, IL. June 20, 2007
  55. Phuphanich S, Supko J, Carson KA, et al: Phase I trial of bortezomib in adults with recurrent malignant glioma: ASCO Meeting Abstracts. Atlanta, GA. June 20 2006
  56. Kunwar S, Prados MD, Chang SM, et al. Direct intracerebral delivery of Cintredekin Besudotox (IL13-PE38QQR) in recurrent malignant glioma: A report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol. 2007;25:837–844
  57. Weaver M, Laske DW. Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J Neurooncol. 2003;65:3–13

PII: S1053-4296(09)00019-8

doi: 10.1016/j.semradonc.2009.02.003

Seminars in Radiation Oncology
Volume 19, Issue 3 , Pages 150-154 , July 2009

Article Tools